Accelerated radiation treatment effective for noninvasive breast cancer

June 29, 2012 in Cancer

Accelerated whole breast irradiation after lumpectomy is an effective treatment for ductal carcinoma in situ (DCIS), a very common early stage and noninvasive form of breast cancer, meaning many more breast cancer patients could see their treatment times reduced by half, according to a study in the June issue of the International Journal of Radiation Oncology•Biology•Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO).

The widespread use of mammography beginning in the early 1980s has led to a dramatic increase in the number of DCIS instances detected, making this one of the most common forms of . Multiple studies have proven that lumpectomy plus radiation significantly reduces the risk of recurrence in both noninvasive and invasive breast cancers and for DCIS, the current standard of treatment is lumpectomy followed by five to six weeks of whole breast radiation.

However, for invasive cancers, the use of an accelerated form of radiation that increases the strength of the dose per treatment and uses fewer treatment sessions overall has been well-established as effective, providing patients with a shorter treatment time with similar positive results. The effectiveness of an accelerated treatment time has not been established for DCIS.

Researchers in the study followed 145 DCIS patients who were treated with lumpectomy and accelerated whole breast irradiation or with accelerated whole plus an additional daily boost. At five years post-treatment, only 4.1 percent of patients experienced a recurrence, which is comparable to the five to 10 percent recurrence rate demonstrated in randomized trials for patients receiving standard radiation.

"The results of our study suggest that DCIS patients can be safely treated with a shorter regimen of radiotherapy," Silvia Formenti, MD, senior author of the study and a radiation oncologist at New York University School of Medicine, said. "This is good news for many who would prefer to receive their treatments in a shorter period of time, but also want the peace of mind that they are receiving the most effective treatment available."

Journal reference: International Journal of Radiation Oncology*Biology*Physics search and more info website

Provided by American Society for Radiation Oncology search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

ASCO: combo antibody therapy effective for melanoma

(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...

Cancer created 13 hours ago | popularity not rated yet | comments 0

Risk factors ID'd for poor cutaneous cell CA outcomes

(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...

Cancer created 14 hours ago | popularity not rated yet | comments 0 | with audio podcast

Physical & emotional impairments common, often untreated in people with cancer

A new review finds cancer survivors suffer a diverse and complex set of impairments, affecting virtually every organ system. Writing in CA: A Cancer Journal for Clinicians, Julie Silver, M.D., associate professor at Harvar ...

Cancer created 18 hours ago | popularity not rated yet | comments 0

Calif. doc with 'cancer cure' gets 14 years prison (Update)

(AP)—A California doctor has been sentenced to 14 years in federal prison for bilking her patients out of more than $1 million by promising that an herbal supplement could cure late-stage cancer and other diseases.

Cancer created 19 hours ago | popularity not rated yet | comments 0

New protein-targeting drug shows promise in early trial for patients with high-risk CLL

A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...

Cancer created 20 hours ago | popularity not rated yet | comments 0 | with audio podcast


AIDS science at 30: 'Cure' now part of lexicon

Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.

Temporal processing in the olfactory system

The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...

Melon focus headband turns to Kickstarter for rollout plans

(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...

For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests

Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...

Now we know why old scizophrenia medicine works on antibiotics-resistant bacteria

In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...

Study identifies new approach to improving treatment for MS and other conditions

(Medical Xpress)—Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved ...